Article
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.
The pharmacogenomics journal - 1 Jan 2017
Quteineh L, Bochud P-Y, Golshayan D, Crettol S, Venetz J-P, Manuel O, Kutalik Z, Treyer A, Lehmann R, Mueller N J, Binet I, van Delden C, Steiger J, Mohacsi P, Dufour J-F, Soccal P M, Pascual M, Eap C B
Abstract excerpt
Metabolic syndrome after transplantation is a major concern following solid organ transplantation (SOT). The CREB-regulated transcription co-activator 2 (CRTC2) regulates glucose metabolism. The effect of CRTC2 polymorphisms on new-onset diabetes after transplantation (NODAT) was investigated in a discovery sample of SOT recipients (n1=197). Positive results were tested for replication in two samples from the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.